Methods The UK Clinical Practice Research Data-link (CPRD) was used to identify 1605 incident cases of SLE from 1997 to 2005 and matched 1:4 to 6284 controls by birth year, gender, general practice and year of first continuous registration. Odds ratios (ORs) of comorbidities at diagnosis and hazards ratios (HRs) after diagnosis of SLEs were estimated adjusting for age, sex, diagnosis year, body mass index, smoking and alcohol consumption.

Results SLE was associated with a higher risk for pre-existing comorbidities, with adjusted ORs (95% confidence interval [CI]) of 2.25 (1.97–2.56), 3.37 (2.49–4.57) and 3.54 (1.89–6.63) for the Charlson index of 1–2, 3–4 and ≥5, respectively. SLE was associated with an adjusted HR (95% CI) of 1.30 (95% CI, 1.13–1.49) for developing new comorbidity after the SLE diagnosis. SLE was associated with a greater risk for cancer, cardiovascular, renal, liver, rheumatological and neurological diseases as well as hypothyroidism, psychosis and anaemia. The development of comorbidities was most frequent in the first two years of SLE diagnosis. Patients with SLE also had high risk of death compared with the control group, with a HR of 1.91 (95% CI, 1.62–2.26).

Conclusions SLE patients had a burden of pre-existing comorbidities at diagnosis and the risk of development of multiple comorbidities were higher after the diagnosis compared to matched controls.

**THE PHARMACOTHERAPEUTIC PATTERN OF LUPUS NEPHRITIS PATIENTS AND ITS EFFECT ON THE HOSPITALISATION COST IN CHINA**

T. Li Renji Hospital- Shanghai JiaoTong University School of Medicine, Department of Rheumatology, Shanghai, China

10.1136/lupus-2017-000215.172

**Abstracts**

Background and aims To investigate the pharmacotherapeutic pattern of patients with lupus nephritis in China and its impact on the hospitalisation cost.

Methods Data were identified by the primary diagnosis of lupus nephritis from the electronic medical record system for retrospective analysis. All treatment drugs were divided into rheumatic drugs and non-rheumatic drugs for study. The hospitalisation expenses, drug utilisation rate, and its impact on the total cost were analysed.

Results 305 patients with LN between January 2014 and December 2015 were included in this study. The average hospitalisation cost was $2109.26, including medical service fees, nursing fees, diagnosis fees, etc. Among them, drug cost was accounted for the high proportion ($1041.41, 49.37%), of which the non-rheumatic drugs were accounted for the major proportion ($892.16, 87.70%). In non-rheumatic drugs, alimentary system drug had the high utilisation rate ($147.74, 95.03%); antimicrobial drugs had the most per person cost ($581.76, 55.30%). According to the result of principal component analysis, the first principal component, which contains antimicrobial drugs and the alimentary system drugs, accounted for 77.3% cumulative variance contribution rate. Therefore, the cost of the first principal component had a great impact on the total cost. Based on result of the association analysis, the prescription of $1 GCs would produce $2.76 alimentary system drugs and $2.76 anti-osteoporosis drugs to prevent adverse reactions of GCs.

Conclusions Decrease in the cost of antibiotics and alimentary system drugs could significantly reduce the patient’s hospitalisation expenses. To save the disease burden, the cost of drugs for the prevention of GC adverse reactions also should be properly managed.

**ELDERLY SLE PATIENTS WITH PREVIOUS SKIN HERPES INFECTION AND HIGHER DOSE OF STEROID ENHANCED THE RISK OF SEVERE HERPES SIMPLEX INFECTION: A NATIONWIDE STUDY**

1TH Li*, 3YS Changa, 4CC Lai, 4CT Tsai. 4Taichung Veterans general hospital – Chiai branch, Division of Allergy- Immunology- and Rheumatology- Department of Medicine, Chiai City, Taiwan R.O.C; 2National Yang-Ming University, Institute of Clinical Medicine, Taipei, Taiwan R.O.C; 3Shuang-Ho Hospital- Taipei Medical University, Division of Allergy-Immunology- and Rheumatology- Department of Internal Medicine, New Taipei City, Taiwan R.O.C; 4Taipei Veterans General Hospital, Division of Allergy- Immunology- and Rheumatology- Department of Medicine, Taipei City, Taiwan R.O.C.

10.1136/lupus-2017-000215.173

Background and aims Systemic lupus erythematosus (SLE) patients are susceptible to herpes simplex virus (HSV) infection, which is occasional but often leading to overwhelming disease such as encephalitis and keratitis. However, only few attempts have been made at the associated incidence and risk factors.

Methods We enrolled SLE patients from the Taiwanese National Health Insurance research database between 1997 and 2012. We compared the incidence rate (IR) of severe HSV infection, including viral septicemia, meningoencephalitis, ocular infection, visceral infection and those with complications after infection, with those of non-SLE cohort. We also evaluated the risk factors of severe HSV infection by means of Cox multivariable proportional hazards model.

Results A total of 1 22 520 subjects (24 504 SLE patients and 98 016 age- and gender-matched subjects as control group) were analysed and revealed a significantly higher IR of severe HSV infection in SLE (Incidence rate ratio=3.52, p<0.001). Previous skin infection (HR=2.17, p=0.047), intravenous steroid pulse therapy (HR=4.48, p<0.001), oral daily steroid dose over 7.5 mg prednisolone or equivalent (HR=1.60, p=0.010) were independent risk factors for severe HSV infection in SLE patients, while age ≤18 (HR=0.47, p=0.021) was a protective factor.

Conclusions A higher risk of severe HSV infection was observed in SLE patients. The risk factors for severe HSV infection were age over 18, previous skin infection, intravenous steroid pulse therapy and an oral daily steroid dose over 7.5 mg.

**THE RELEVANCE OF VASCULAR EVALUATION IN SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM AN INCEPTION COHORT**

1R Lizola*, 1CA Hinojosa, H Laparra, 1JE Anaya-Ayala, 2LA Mendosa, 2M Ocampo, 2J Romero-Díaz. 1Instituto Nacional de Ciencias Médicas y Nutrición “Salvador Zubirán”; Vascular Surgery, Mexico city, Mexico; 2Instituto Nacional de Ciencias Médicas y Nutrición “Salvador Zubirán”, Rheumatology, Mexico City, Mexico

10.1136/lupus-2017-000215.174

Background and aims Systemic lupus erythematosus (SLE), as a chronic inflammatory disease, has been associated with